Genotype-dependent time course of lymphocyte beta 2-adrenergic receptor down-regulation

Clin Pharmacol Ther. 2003 Sep;74(3):255-63. doi: 10.1016/S0009-9236(03)00188-7.

Abstract

Background: Volunteers homozygous for Glu27 beta(2)-adrenergic receptor (beta(2)AR) polymorphism have delayed onset of agonist-induced desensitization of cardiac beta(2)AR responses.

Methods and results: To determine whether this can also be demonstrated for Glu27Glu beta(2)AR natively expressed in circulating lymphocytes, we assessed the effects of 2 weeks of oral treatment with 3 x 5 mg/d terbutaline on lymphocyte beta(2)AR density (determined by [-]-[iodine 125]iodocyanopindolol binding) and responsiveness (assessed as [-]-isoproterenol hydrochloride [INN, isoprenaline] [1 nmol/L to 1 micromol/L]-induced lymphocyte cyclic adenosine monophosphate increases) in 23 healthy volunteers (13 with wild-type beta(2)AR [group A], 5 homozygous for Glu27 with Gly16Gly or Arg16Gly [group B], and 5 homozygous for Gly16 with Gln27Gln or Gln27Glu [group C]). Before terbutaline treatment, lymphocyte beta(2)AR density and isoproterenol-induced lymphocyte cyclic adenosine monophosphate accumulation were not significantly different in the genotype groups; 2 weeks of terbutaline treatment significantly decreased lymphocyte beta(2)AR density and responsiveness in the 3 genotype groups to a nearly identical extent, and no differences were observed. In time-course studies, however, in groups A and C lymphocyte beta(2)AR showed significant (P <.05, repeated-measures ANOVA) down-regulation as early as 24 hours after the first terbutaline intake, whereas in group B significant (P <.05, repeated-measures ANOVA) beta(2)AR decreases were observed only 72 hours after the first terbutaline intake. Thus the time course of lymphocyte beta(2)AR down-regulation in group B was significantly (P <.01, 2-way ANOVA) different from that in groups A and C.

Conclusion: The extent of lymphocyte beta(2)AR down-regulation after long-term terbutaline treatment in volunteers homozygous for the Gly16 or Glu27 beta(2)AR polymorphism was genotype-independent and was nearly identical to that in wild-type beta(2)AR volunteers. However, the onset of beta(2)AR down-regulation was delayed in volunteers homozygous for the Glu27 beta(2)AR polymorphism.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Agonists / pharmacokinetics
  • Adrenergic beta-Antagonists / pharmacokinetics
  • Adult
  • Binding Sites
  • Codon / genetics
  • Cyclic AMP / metabolism
  • Down-Regulation / genetics*
  • Female
  • Genotype*
  • Heart Rate / drug effects
  • Humans
  • Iodocyanopindolol / pharmacokinetics
  • Kinetics
  • Lymphocytes / metabolism*
  • Male
  • Myocardial Contraction / drug effects
  • Polymorphism, Genetic / genetics
  • Receptors, Adrenergic, beta-2 / biosynthesis*
  • Receptors, Adrenergic, beta-2 / genetics*
  • Terbutaline / pharmacokinetics

Substances

  • Adrenergic beta-Agonists
  • Adrenergic beta-Antagonists
  • Codon
  • Receptors, Adrenergic, beta-2
  • Iodocyanopindolol
  • Cyclic AMP
  • Terbutaline